Charlie McDermott

Mr. McDermott has 20 years of operating experience in the biotechnology and ophthalmology industries and currently serves as Kala’s Interim President and CBO. Previously he served as Vice President of Business Development, Eye Care and Drug Delivery at Allergan, and established partnerships that ranged from novel platforms (DARPins, PEMs, siRNA, etc.) to commercial products such as Acular™, Acuvail™, Latisse™ and Lastacaft™. Before joining Allergan, Mr. McDermott worked deCODE Genetics and Agouron Pharmaceuticals in business development, drug discovery, and regulatory affairs roles. Mr. McDermott holds degrees in business (MBA), Molecular Biology (MA), and Biochemistry (BA).